PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2032³â)
PARP Inhibitor Biomarkers Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
»óǰÄÚµå : 1701659
¸®¼­Ä¡»ç : Persistence Market Research
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 180 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,995 £Ü 7,227,000
Unprintable PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ º¹»ç, ÀμⰡ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,295 £Ü 10,555,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.
US $ 8,495 £Ü 12,291,000
PDF & Excel (Corporate User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÁÖ¿ä Á¶»ç °á°ú

PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå - º¸°í¼­ ¹üÀ§

PARP(Æú¸® ADP ¸®º¸½º ÁßÇÕÈ¿¼Ò) ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿´Â PARP ¾ïÁ¦Á¦ Ä¡·áÀÇ ÇýÅÃÀ» ¹ÞÀ» ¼ö Àִ ȯÀÚ¸¦ ½Äº°ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϸç, ƯÈ÷ Á¾¾ç ºÐ¾ß¿¡¼­ Áß¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹ÙÀÌ¿À¸¶Ä¿¿¡´Â BRCA1/2 µ¹¿¬º¯ÀÌ, »óµ¿ ÀçÁ¶ÇÕ º¹±¸ °á¼Õ(HRD), ±âŸ DNA ¼Õ»ó ¹ÝÀÀ(DDR) °æ·ÎÀÇ º¯È­°¡ Æ÷ÇԵ˴ϴÙ. ½ÃÀåÀº ƯÈ÷ ³­¼Ò¾Ï, À¯¹æ¾Ï, Àü¸³¼±¾Ï, ÃéÀå¾Ï µîÀÇ Ä¡·á¿¡ ÀÖ¾î ÀÓ»óÀǸ¦ Áö¿øÇÔÀ¸·Î½á Á¤¹Ð Á¾¾çÇÐ Áø·á¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý Ä¡·á Á¢±Ù¹ýÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. À¯Àüü ÇÁ·ÎÆÄÀϸµ, Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS), µ¿¹ÝÁø´ÜÀÇ ¹ßÀüÀÌ ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

¼¼°è PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº ¾Ï ¹ßº´·ü Áõ°¡¿Í Ç¥ÀûÄ¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖÀ¸¸ç, PARP ¾ïÁ¦Á¦°¡ ¿©·¯ ¾Ï¿¡ ´ëÇÑ Ä¡·áÁ¦·Î ½ÂÀεʿ¡ µû¶ó ¹ÙÀÌ¿À¸¶Ä¿ »óŸ¦ ±â¹ÝÀ¸·Î Àû°Ý ȯÀÚ¸¦ ½Äº°ÇÏ´Â µ¿¹ÝÁø´Ü °Ë»ç¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. PARP ¾ïÁ¦Á¦¿¡ ´ëÇÑ ¹ÝÀÀ¼º ¿¹ÃøÀÎÀÚ·Î BRCA À¯ÀüÀÚ º¯ÀÌ ¹× HRD¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¹ÙÀÌ¿À¸¶Ä¿ °Ë»çÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯Áö¿ä¹ý ¹× º´¿ë¿ä¹ý¿¡¼­ PARP ¾ïÁ¦Á¦ÀÇ »ç¿ëÀÌ È®´ëµÇ¸é¼­ ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤¹Ð Á¾¾çÇп¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿ø°ú À¯Àüü ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ È®´ëµµ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¾ïÁ¦¿äÀÎ

PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº Å« ¼ºÀå ÀáÀç·Â¿¡µµ ºÒ±¸ÇÏ°í ¿©·¯ °¡Áö Á¦¾à¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç ¹× Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼® ±â¼ú°ú °ü·ÃµÈ ³ôÀº ºñ¿ë, ƯÈ÷ ÁßÀú¼Òµæ Áö¿ª¿¡¼­´Â ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. µ¿¹ÝÁø´Ü ¾àǰ¿¡ ´ëÇÑ »óȯ Àå¾Ö¹°°ú º¹ÀâÇÑ ±ÔÁ¦´Â »õ·Î¿î °Ë»çÀÇ ½ÃÀå ÁøÀÔÀ» Áö¿¬½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, PARP ¾ïÁ¦Á¦ÀÇ Àû°Ý¼ºÀ» °Ë»çÇÏ´Â ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç¿¡ ´ëÇÑ ÀÓ»óÀÇ¿Í È¯ÀÚµéÀÇ ÀνÄÀÌ Á¦ÇÑÀûÀ̾ ±¤¹üÀ§ÇÑ Ã¤ÅÃÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. °Ë»ç ±âÁØÀÇ ÆíÂ÷ ¹× Àü¹® °Ë»ç ½Ã¼³¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ¹Ì°³¹ß Áö¿ª¿¡¼­ÀÇ ½ÃÀå È®´ë¸¦ ´õ¿í Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ±âȸ

PARP ¾ïÁ¦Á¦ÀÇ Àû¿ë ¹üÀ§¸¦ È®´ëÇÒ ¼ö ÀÖ´Â BRCA À¯ÀüÀÚ º¯ÀÌ ÀÌ¿ÜÀÇ ½Å±Ô ¹ÙÀÌ¿À¸¶Ä¿ °³¹ß¿¡´Â Å« ±âȸ°¡ Á¸ÀçÇÕ´Ï´Ù. µ¿¹ÝÁø´ÜÀ» °øµ¿ °³¹ßÇÏ´Â Á¦¾à±â¾÷°ú Áø´Ü±â¾÷ °£ÀÇ Á¦ÈÞ´Â À¯¸ÁÇÑ ¼ºÀå ¼ö´ÜÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. À¯Àüü µ¥ÀÌÅÍ ÇØ¼®¿¡ AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕÀº ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö°ú ÀÓ»óÀû ÀÇ»ç°áÁ¤À» °­È­ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ, ¿ø°ÝÀÇ·á¿Í ÀçÅà À¯ÀüÀÚ °Ë»ç Ç÷§ÆûÀÇ º¸±ÞÀÌ È®´ëµÇ¸é¼­ ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç ¹× ȯÀÚ ´ë»ó ¾Æ¿ô¸®Ä¡¿¡ »õ·Î¿î ä³ÎÀÌ Á¦°øµÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ½ÅÈï½ÃÀå ÁøÃâ°ú ¾×ü »ý°Ë ±â¼úÀÇ ÁøÈ­µµ ¹Ì°³¹ßµÈ ¼ºÀå °¡´É¼ºÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°è PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀ» Á¶»çÇÏ¿© ¼ºÀå ÃËÁø¿äÀÎ, µ¿Çâ, ±âȸ, °úÁ¦ µî ½ÃÀå ¿ªÇп¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå ºÎ°¡°¡Ä¡ ÀλçÀÌÆ®

Á¦4Àå ¼¼°èÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á

Á¦5Àå ¼¼°èÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : Áö¿ª

Á¦6Àå ºÏ¹ÌÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á

Á¦7Àå À¯·´ÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á

Á¦8Àå µ¿¾Æ½Ã¾ÆÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á

Á¦9Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á

Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á

Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Persistence Market Research has recently released a comprehensive report on the worldwide market for PARP inhibitor biomarkers. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global PARP inhibitor biomarkers market from 2025 to 2032.

Key Insights:

PARP Inhibitor Biomarkers Market - Report Scope:

PARP (Poly ADP-ribose polymerase) inhibitor biomarkers are crucial in identifying patients who are likely to benefit from PARP inhibitor therapies, particularly in oncology applications. These biomarkers include BRCA1/2 mutations, homologous recombination deficiency (HRD), and other DNA damage response (DDR) pathway alterations. The market caters to precision oncology practices by aiding clinicians in tailoring cancer therapies, particularly for ovarian, breast, prostate, and pancreatic cancers. As the demand for personalized medicine rises, the adoption of biomarker-driven treatment approaches is accelerating. Advancements in genomic profiling, next-generation sequencing (NGS), and companion diagnostics are significantly contributing to market growth.

Market Growth Drivers:

The global PARP inhibitor biomarkers market is driven by the rising prevalence of cancer and increasing demand for targeted therapies. As PARP inhibitors gain regulatory approval for treating multiple cancers, there is a growing need for companion diagnostic tests to identify eligible patients based on biomarker status. The increasing awareness of BRCA gene mutations and HRD as predictors of response to PARP inhibitors is boosting biomarker testing volumes. Furthermore, expanding applications of PARP inhibitors in maintenance therapy and combination treatment regimens have fueled investments in biomarker research. Government initiatives to promote precision oncology and growing investments in genomic medicine infrastructure are also propelling market growth.

Market Restraints:

Despite strong growth potential, the PARP inhibitor biomarkers market faces several limitations. High costs associated with biomarker testing and next-generation sequencing technologies pose challenges, especially in low- and middle-income regions. Reimbursement hurdles and regulatory complexities surrounding companion diagnostics can delay market entry for new tests. Additionally, limited awareness among clinicians and patients about biomarker testing for PARP inhibitor eligibility hinders broader adoption. Variability in testing standards and access to specialized laboratories further restrict market expansion in underdeveloped areas.

Market Opportunities:

Significant opportunities exist in the development of novel biomarkers beyond BRCA mutations, which can broaden the scope of PARP inhibitor applications. Collaborations between pharmaceutical companies and diagnostic firms to co-develop companion diagnostics present a promising growth avenue. The integration of artificial intelligence and machine learning in genomic data interpretation is expected to enhance biomarker discovery and clinical decision-making. Furthermore, the increasing penetration of telemedicine and at-home genetic testing platforms provides new channels for biomarker testing and patient outreach. Expansion into emerging markets and the evolution of liquid biopsy techniques also represent untapped potential for growth.

Key Questions Answered in the Report:

Competitive Intelligence and Business Strategy:

Leading players in the global PARP inhibitor biomarkers market, including Myriad Genetics, Foundation Medicine, Thermo Fisher Scientific, and Illumina, Inc., are investing heavily in innovation, strategic partnerships, and co-development of companion diagnostics. These companies are leveraging their expertise in genomic testing and bioinformatics to develop accurate and efficient biomarker assays. Collaborations with pharmaceutical companies like AstraZeneca, Merck, and GlaxoSmithKline aim to accelerate the development of companion diagnostics aligned with PARP inhibitors. Key strategies include expanding testing portfolios, enhancing NGS capabilities, and strengthening global distribution networks to capture market share in both established and emerging regions.

Key Companies Profiled:

PARP Inhibitor Biomarkers Market Segmentation

By Product:

By Application:

By End User:

By Region:

Table of Contents

1. Executive Summary

2. Market Overview

3. Value Added Insights

4. Global PARP Inhibitor Biomarkers Market Outlook

5. Global PARP Inhibitor Biomarkers Market Outlook: Region

6. North America PARP Inhibitor Biomarkers Market Outlook

7. Europe PARP Inhibitor Biomarkers Market Outlook

8. East Asia PARP Inhibitor Biomarkers Market Outlook

9. South Asia & Oceania PARP Inhibitor Biomarkers Market Outlook

10. Latin America PARP Inhibitor Biomarkers Market Outlook

11. Middle East & Africa PARP Inhibitor Biomarkers Market Outlook

12. Competition Landscape

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â